Navigation Links
Loxo Oncology And Array BioPharma Announce License And Collaboration Agreement
Date:7/10/2013

making excellent progress and we expect to initiate human clinical trials in 2014," said Josh Bilenker, MD, Loxo chief executive officer and a partner in Aisling Capital.  

Array has a consistent track record of successful drug discovery with extensive capabilities in high throughput lead identification, protein-structure-enabled drug design, and diverse chemistry approaches such as competitive, allosteric and covalent target inhibition.  Array has invented 16 drugs which are in clinical development, including 11 currently in Phase 2 or 3 trials. Beyond its wholly-owned hematology/oncology programs, Array has partnered development of Array-invented drugs with companies including Amgen, Astra Zeneca, Celgene, Genentech, Novartis and Oncothyreon.

"We are delighted to enter into this collaboration with the goal of rapidly bringing this exciting technology to cancer patients," said Ron Squarer, chief executive officer, Array BioPharma.  "Array has partnered with a number of venture-backed companies which continue to produce encouraging results; the venture-financed model of drug discovery and development can cost-effectively identify novel candidates and rapidly test the clinical hypothesis." 

As part of the formation of Loxo Oncology, Keith Flaherty, MD, the director of the Henri and Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital, will chair the company's Scientific Advisory Board.  "Having collaborated with small and large companies, I consider Loxo to be ideally constructed to rapidly translate emerging validated targets into therapies.
This collaboration provides a unique opportunity to work with Array chemists and biologists to direct novel agents targeting critical points of signal transduction in cancer to biomarker-defined cancer populations for whom a significant unmet need persists."

Dennis Pu
'/>"/>

SOURCE Array BioPharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
2. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
3. PRISM Pharma Closes $15 million Series C Financing to Advance PRI-724 into Non-oncology Indications
4. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
5. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
6. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
7. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
8. Genomic Health Announces Results of Ten Studies in Breast, Prostate and Colon Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting
9. ViewRays Chief Medical Officer Honored by American Society for Radiation Oncology (ASTRO)
10. Amgen To Webcast Investor Meeting At Upcoming American Society Of Clinical Oncology Annual Meeting
11. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Corporation (Nasdaq: IRIX ) today reported financial results ... , Revenues were $11.8 million in the fourth ... 11% from $10.6 million in the 2013 fourth quarter. Revenues ... from $38.3 million in 2013. , Gross margin for ... the fourth quarter of the prior year. , Operating ...
(Date:3/5/2015)... March 5, 2015  BioPhotas, Inc., an FDA registered ... patented photo-therapeutic technologies to treat skin, muscle and joint ... Semper Fi Fund to provide BioPhotas, flagship product, the ... pain management solutions.  Commenting on the ... who used the Celluma at the Warrior Hope and ...
(Date:3/5/2015)... 5, 2015   ndd Medical Technologies , a ... employs precise ultrasound technology, announced that its EasyOne Pro® ... the San Antonio Pulmonary Fibrosis Support Group. The clinic ... fibrosis (PF), as well as those suspected of having ... a mere 12 square inches, EasyOne Pro provides accurate ...
Breaking Medicine Technology:IRIDEX Reports 2014 Fourth Quarter, Year-End Results 2IRIDEX Reports 2014 Fourth Quarter, Year-End Results 3IRIDEX Reports 2014 Fourth Quarter, Year-End Results 4IRIDEX Reports 2014 Fourth Quarter, Year-End Results 5IRIDEX Reports 2014 Fourth Quarter, Year-End Results 6IRIDEX Reports 2014 Fourth Quarter, Year-End Results 7IRIDEX Reports 2014 Fourth Quarter, Year-End Results 8BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 2BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 3ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 2ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 3
... Aethlon Medical, Inc. (OTC Bulletin Board: ... filtration devices to address infectious disease and cancer, ... entitled: " A Platform to Address Bioterrorism." ... at: http://www.aethlonmedical.com/knowledge-center/special-reports/ ...
... 2010 Northwestern Memorial Hospital is one ... will test whether operable lung cancer patients and their ... by hardwiring data systems to reduce medical error and ... trial co-sponsored by the Commission on Cancer and the ...
Cached Medicine Technology:'A Platform Technology to Address Bioterrorism' Released by Aethlon Medical, Inc. 2'A Platform Technology to Address Bioterrorism' Released by Aethlon Medical, Inc. 3'A Platform Technology to Address Bioterrorism' Released by Aethlon Medical, Inc. 4Lung Cancer Patients the Centerpiece for Northwestern Medicine Quality of Care Study 2Lung Cancer Patients the Centerpiece for Northwestern Medicine Quality of Care Study 3
(Date:3/6/2015)... As the Association of American ... 90,000 doctors by 2025 is updated this week and ... is proactively preparing by analyzing demographics and pursuing viable ... , Several factors including the increasing number of retiring ... the Affordable Care Act and an uneven distribution of ...
(Date:3/6/2015)... Many patients with knee osteoarthritis have continued ... (or someone you know) have chronic pain and problems ... interested in the ACT-OA clinical trial. , Kevin ... is one of fifteen physicians in the U.S. to ... as part of a new, multi-site, double blind, placebo-controlled ...
(Date:3/6/2015)... March 06, 2015 Utilizing the latest ... rapidly reach their ideal weight has enabled Diet Doc ... to their already impressive collection of fat loss enhancement ... clients special promotions and savings to help people throughout ... This promotion is especially appealing to new clients ...
(Date:3/6/2015)... TX (PRWEB) March 06, 2015 ... publishing company, created a unique ‘energy’ experiment to ... lives. , After quick ‘5 -7 ... more than 150+ countries reported their life improving ... respondents reported positive results. , According to research, ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 Dr. Mark Sowell ... Education in Scottsdale, AZ. Offering programs for advanced education in ... over the world. , As a visiting faculty member ... “teach and learn” each time he visits Spear Education to ... Dr. Sowell remarks, “we are training only the top 10% ...
Breaking Medicine News(10 mins):Health News:Susquehanna Health Plans Progressively to Prevent Projected Physician Shortfall 2Health News:Susquehanna Health Plans Progressively to Prevent Projected Physician Shortfall 3Health News:Susquehanna Health Plans Progressively to Prevent Projected Physician Shortfall 4Health News:Kevin Darr, M.D. is Now Enrolling Patients in a New FDA-Approved Clinical Trial Evaluating Adipose-Derived Regenerative Cells in the Treatment of Knee Osteoarthritis 2Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 2Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 3Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 4Health News:250,000+ Person ‘Remote Energy’ Event has 94.2% of Respondents saying “Life Got Better” 2Health News:Plano Dentist Teaches Dentists from Around the Globe at Spear Education 2
... feminized after chemicals, such as the pharmaceutical ethinylestradiol, made it ... Creek, are taking longer to become feminized after a plant ... study. The results will be presented Sunday at The Endocrine ... levels of the chemicals that the fish swam in were ...
... ... , ... 2010 -- As the leading voice for women and men facing infertility, RESOLVE: The ... the commitment IntegraMed has for RESOLVE’s mission of patient support and education. , ...
... ... the Enterprise Architecture Profession (CAEAP) has published version one of the Enterprise Architecture Professional Practice ... ... For Free | Click Here To Download: , ,These abstracts provide the enterprise architect,s ...
... The United States Department of Defense Spinal Cord Injury Research ... a million dollars U.S. to support research at the Robarts ... The spinal cord injury research team of Gregory Dekaban, Arthur ... Kwon of the University of British Columbia and Kyle Petersen ...
... ... Injection, this is a procedure Dr. Manish Gupta offers at Specialty Orthopedic Center of Boca ... (PRWEB) June ... conference and the focus was not on his golf game or his recent lack of. ...
... ... for Alkaline Diet , many of their subscribers and readers demand for more alkaline ... (PRWEB) ... food store offering natural health and dieting products from all over the world. Since the ...
Cached Medicine News:Health News:Chemicals remaining after wastewater treatment change the gender of fish 2Health News:RESOLVE: The National Infertility Association Announces Partnership with Attain Fertility 2Health News:Enterprise Architecture -- Breaking Away From The Pack 2Health News:US Department of Defense helps move spinal cord injury treatment closer to clinical trials 2Health News:Tiger Takes Another Shot: PRP Injections Put On the Spot 2Health News:Official Alkaline Diet Site Launches Organic Food Store for Healthy Living And Natural Weight Loss 2Health News:Official Alkaline Diet Site Launches Organic Food Store for Healthy Living And Natural Weight Loss 3
The Ahmed Glaucoma Valve has been successfully demonstrated to work in all types of glaucoma cases, particularly neovascular, congenital and uvietic glaucoma....
Ahmed Glaucoma Valve Flexible Plate ....
... a robust and durable drainage system. Preplaced ... globe. Pressure Ridge Molteno Implants have a ... tissue, acts as a Pressure sensitive biological ... implants allows the surgeon to choose the ...
... Baerveldt Glaucoma Implants feature a low implant ... reduced complications. The single-quadrant insertion is technically ... seton plate to be installed with less ... fenestrations of the Baerveldt implant were designed ...
Medicine Products: